Invasive breast carcinoma Trials in Racine, United States
Conditions / Invasive breast carcinoma / Racine, United States
Clinical trials for Invasive breast carcinoma investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04001829 | Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | RECRUITING | — |
| NCT04266249 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |